Exact Sciences and the Mayo Clinic are working to develop a blood test for pancreatic cancer that might be able to diagnose patients with early-stage disease.
The FLASH method, which depletes unwanted DNA from samples, allows labs to perform deep metagenomic sequencing on smaller, less expensive instruments.
During its earnings call this week, the liquid biopsy firm said it is planning a 10,000-patient trial to test its Lunar assay for colorectal cancer screening.
The index, which underperformed the Dow Jones and the Nasdaq, fell nearly 3 percent in April.
The firm recently submitted an application to the US Food and Drug Administration to expand Cologuard's label to the 45 to 49 age group.
The firm reported that test volumes for its Cologuard colorectal cancer screening test also rose 79 percent year over year.
The company said it will use part of the proceeds to repurchase some of its senior notes due in January 2025, and the rest for corporate purposes.
The company said test volume for its Cologuard colorectal cancer test rose 66 percent during the quarter to 292,000.
The startup, which was founded by two Washington University researchers and a Wharton MBA, is looking to take a big bite out of Cologuard's market.
The test, which searches for fragments of DNA 200 basepairs or longer that are characteristic of diseased mucosa, may eventually compete with diagnostics like Exact Sciences' Cologuard.
Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.
University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.
The Wall Street Journal examines billing codes used by uBiome.
In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.